VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
TFX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
TFXTeleflex Incorporated
$129.75$5.7B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

TFX logoTeleflex Incorporated(TFX)Earnings, Financials & Key Ratios

TFX•NYSE
$129.75
Price updated Jul 7, 2026
SectorHealthcareIndustryMedical InstrumentsSub-IndustrySurgical and interventional devices
AboutTeleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.Show more
  • Revenue$1.99B-34.6%
  • EBITDA$434M+1.9%
  • Net Income-$906M-1399.8%
  • EPS (Diluted)-20.25-1468.2%
  • Gross Margin56.24%+0.7%
  • EBITDA Margin21.76%+55.8%
  • Operating Margin12.84%+159.0%
  • Net Margin-45.45%-2087.7%
  • ROE-24.47%-1630.9%

TFX Price & Volume

Teleflex Incorporated (TFX) stock price & volume — 10-year historical chart

Loading chart...

Strategic Divestiture Reshapes Teleflex Financial Foundation

Investment Thesis • Updated 2026Q1

VerdictNeutral
Growth:Contracting
Profitability:Strained
Financial:Healthy
Cash Flow:Mixed
Primary Risk:UroLift market saturation risk

Key Thesis Takeaways

  • Teleflex is currently navigating a complex portfolio transition, highlighted by a 21.8% revenue contraction in 2026Q1 following the divestiture of its respiratory business.
  • While the company has successfully deleveraged its balance sheet to a 0.06 debt-to-equity ratio, investors should monitor the potential market saturation of the UroLift franchise and the persistent pressure on SG&A expenses, which consumed $226.0 million in the most recent quarter.
  • Future performance hinges on the company's ability to stabilize core interventional growth while managing the $2.3 billion in goodwill that remains on the balance sheet.

Verdict Logic

while the dramatic reduction in debt to a 0.06 D/E ratio is a positive development, the negative 1.5% net margin and the 21.8% revenue decline in 2026Q1 suggest that the company's operational turnaround remains in a high-risk, early stage.

TFX Growth Metrics

Teleflex Incorporated (TFX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years0.97%
5 Years-4.72%
3 Years-10.62%
TTM-6.61%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-775.29%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-819.24%

Return on Capital

10 Years6.94%
5 Years6.34%
3 Years4.65%
Last Year4.05%

TFX Recent Earnings

Teleflex Incorporated (TFX) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 7, 2026
Metric
Actual
Est
EPS
$1.39+14.9%
$1.21
Rev
$548M+2.1%
$537M
Q1 2026
Feb 26, 2026
Metric
Actual
Est
EPS
$1.93-48.3%
$3.73
Rev
$569M-38.1%
$919M
Q4 2025
Nov 6, 2025
Metric
Actual
Est
EPS
$3.67+8.6%
$3.38
Rev
$913M-0.2%
$915M
Q3 2025
Jul 31, 2025
Metric
Actual
Est
EPS
$3.73+11.0%
$3.36
Rev
$781M-12.5%
$893M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 7, 2026
$1.39vs $1.21+14.9%
$548Mvs $537M+2.1%
Q1 2026Feb 26, 2026
$1.93vs $3.73-48.3%
$569Mvs $919M-38.1%
Q4 2025Nov 6, 2025
$3.67vs $3.38+8.6%
$913Mvs $915M-0.2%
Q3 2025Jul 31, 2025
$3.73vs $3.36+11.0%
$781Mvs $893M-12.5%
Based on last 12 quarters of dataView full earnings history →

Latest TFX News

Recent stock market news and headlines for Teleflex Incorporated (TFX)

Business Wire·22h ago
Teleflex Publishes 2025 Global Impact Report

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2025 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company's Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Climate-Related Financial Disclosures (TCFD). “This yea.

Zacks Investment Research·Jun 24, 2026
Do Options Traders Know Something About Teleflex Stock We Don't?

Investors need to pay close attention to TFX stock based on the movements in the options market lately.

Business Wire·Jun 23, 2026
Teleflex Initiates Enrollment in Global BIOMAG™‑III Pivotal Trial of Freesolve™ Resorbable Magnesium Scaffold

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the beginning of enrollment in the BIOMAG™‑III Study (NCT07258290), a landmark global study evaluating the Freesolve™ Resorbable Magnesium Scaffold (RMS). Dr. Itsik Ben-Dor, MedStar Health in Washington, D.C., is the first implanter in the United States (U.S.) in the IDE trial of Freesolve™ RMS. Designed as a pivotal trial to support future regulatory applications,.

Peers Comparison

Key metrics vs top competitors for Teleflex Incorporated (TFX)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
TFX logoTFXTeleflex IncorporatedCurrent
$129.75$5.74B-6.41-34.61%-45.45%-24.47%1.04%
ICU logoICUSeaStar Medical Holding Corporation
$5.07$198.66M-0.87814.07%-828.62%-146.29%—
UTMD logoUTMDUtah Medical Products, Inc.
$69.33$220.75M19.92-5.83%28.9%9.13%—
ATRC logoATRCAtriCure, Inc.
$32.80$1.66B-136.6714.88%-0.83%-0.95%—
NVCR logoNVCRNovoCure Limited
$17.72$2.02B-14.528.28%-25.66%-50.82%—
ANGO logoANGOAngioDynamics, Inc.
$13.07$540.04M-15.75-3.76%-10%-17.65%—

Compare TFX vs Peers

Teleflex Incorporated (TFX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ICU

Most directly comparable listed peer for TFX.

Scale Benchmark

vs ABT

Larger-name benchmark to compare TFX against a more recognizable public peer.

Peer Set

Compare Top 5

vs ICU, UTMD, ATRC, NVCR

TFX SEC Filings & Documents

Teleflex Incorporated (TFX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 7, 2026·SEC

Material company update

Apr 30, 2026·SEC

Material company update

Mar 27, 2026·SEC

10-K Annual Reports

4
FY 2026

Feb 27, 2026·SEC

FY 2025

Feb 28, 2025·SEC

FY 2024

Feb 23, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 7, 2026·SEC

FY 2025

Nov 6, 2025·SEC

FY 2025

Jul 31, 2025·SEC

Get notified when TFX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

TFX Frequently Asked Questions

Teleflex Incorporated (TFX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Teleflex Incorporated's revenue?

Teleflex Incorporated (TFX) reported $2.81B in revenue for fiscal year 2025. This represents a 202% increase from $931.2M in 1996.

How fast is Teleflex Incorporated growing?

Teleflex Incorporated (TFX) saw revenue decline by 34.6% over the past year.

Is TFX profitable?

Teleflex Incorporated (TFX) reported a net loss of $1.01B for fiscal year 2025.

Dividend & Returns
Does TFX pay dividends?

Yes, Teleflex Incorporated (TFX) pays a dividend with a yield of 1.04%. This makes it attractive for income-focused investors.

What is TFX's return on equity?

Teleflex Incorporated (TFX) has a return on equity (ROE) of -24.5%. Negative ROE indicates the company is unprofitable.

What is Teleflex Incorporated's free cash flow?

Teleflex Incorporated (TFX) generated $249.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in TFX back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →